PTPA and cancer: As reviewed extensively elsewhere (Carratu et al., 2016; Grech et al., 2016; Lambrecht et al., 2013; O'Connor et al., 2017; Perrotti & Neviani, 2013), PP2A-activating drugs (PADs) are being sought and developed by cancer researchers in academia and the pharmaceutical industry.